Psychopharmacological and psychotherapeutic treatment of borderline personality disorder;Pharmakologische und psychotherapeutische behandlung der borderline-störung

Zeitschrift fur Psychiatrie, Psychologie und Psychotherapie

Volumn 54, Issue 3, 2006, Pages 185-197

  Remmel, Andreas ^a,b   Bohus, Martin ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Borderline personality disorder; Pharmacotherapy; Psychotherapy; Randomized controlled trials; Therapeutic strategies

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; MODAFINIL; MOOD STABILIZER; NALOXONE; NALTREXONE; NARCOTIC ANTAGONIST; NEUROLEPTIC AGENT; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; OMEGA 3 FATTY ACID; PHENELZINE; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

BEHAVIOR THERAPY; BORDERLINE STATE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFECT; HAMILTON SCALE; HUMAN; PROGNOSIS; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SYMPTOM CHECKLIST 90;

EID: 33746565420     PISSN: 16614747     EISSN: None     Source Type: Journal    
DOI: 10.1024/1661-4747.54.3.185     Document Type: Review

References (71)

1. Anghelescu, I., Jänen, B., Schindler, F. & Lammers, C. (2005). Worsening of borderline symptoms under reboxetine treatment. Journal of Neuropsychiatry and Clinical Neuroscience, 17, 559-560.
2. Arntz, A., van den Hoorn, M., Cornelis, J., Verheul, R., van den Bosch, Wies, M. C. & de Boer, S. F. (2003). Reliability and validity of the Borderline Personality Disorder Severity Index. Journal of Personality Disorders, 17, 45-59.
3. Bateman, A. W. & Fonagy, P. (1999). Effectiveness of partial hospitalization in the treatment of borderline personality disorder: A randomized controlled trial. American Journal of Psychiatry, 156, 1563-1569.
4. Bateman, A. W. & Fonagy, P. (2001). Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: An 18-month follow-up. American Journal of Psychiatry, 158, 36-42.
5. Binks, C. A., Fenton, M., McCarthy, L., Lee, T., Adams, C. E. & Duggan, C. (2006). Pharmacological interventions for people with borderline personality disorder (Review). The Cochrane Database of Systematic Reviews, 1, 1-83.
6. Bogenschutz, M. P. & George Nurnberg, H. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104-109.
7. Bohus, M., Haaf, B., Simms, T., Limberger, M. F., Schmahl, C. G., Unckel, C., Lieb, K. & Linehan, M. M. (2004). Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: A controlled trail. Behavior Research and Therapy, 42, 487-499.
8. Bohus, M., Landwehrmeyer, C. B., Stiglmayr, C. E., Limberger, M. F., Böhme, E. R. & Schmahl, C. G. (1999). Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorders: An open-label trial. Journal of Clinical Psychiatry, 60, 598-603.
9. Bohus, M., Limberger, M., Frank, U., Chapman, A., Kühler, Th. & Stieglitz, R. D. (in press). Psychometric properties of the Borderline Symptom List (BSL). Psychopathology.
10. Bohus, M., Limberger, M. F., Frank, U., Sender, I., Gratwohl, T. & Stieglitz, R. D. (2001). Entwicklung der Borderline-Symptom-Liste. Psychotherapie, Psychosomatik, Medizinische Psychologie, 51, 201-211.
11. Bohus, M. & Schmahl, C. (2001). Therapeutische Prinzipien der dialektisch-behavioralen Therapie für Borderline-Störungen. Persönlichkeitsstörungen: Theorie und Therapie 5, S91-S102.
12. Bohus, M., Schmahl, C. G. & Lieb, K. (2004). New developments in the neurobiology of borderline personality disorder. Current Psychiatry Reports 6, 43-50.
13. Clarkin, J. F., Foelsch, P. A., Levy, K. N., Hull, J. W., Delaney, J. C. & Kernberg, O. F. (2001). The development of a psychodynamic treatment for patients with borderline personality disorder: A preliminary study of behavioral change. Journal of Personality Disorders, 15, 487-495.
14. Coccaro, E. F. & Kavoussi, R. J. (1997). Fluoxetine and impulsive aggressive behaviour in personality-disordered subjects. Archives of General Psychiatry, 54, 1081-1088.
15. Cornelius, J. R., Soloff, P. H., Perel, J. M. & Ulrich, R. F. (1990). Fluoxetine trial in borderline personality disorder. Psychopharmacology Bulletin, 26, 151-154.
16. Cowdry, R. W. & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of General Psychiatry, 45, 111-119.
17. Frances, A., Fyer, M. & Clarkin, J. F. (1986). Personality and suicide. Annals of the New York Academy of Sciences, 487, 281-293.
18. Frankenburg, F. R. & Zanarini, M. C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo controlled pilot study. Journal of Clinical Psychiatry, 63, 442-446.
19. Grilo, C. M., Sanislow, C. A., Gunderson, J. G., Pagano, M. E., Yen, S., Zanarini, M. C., Shea, M.T., Skodol, A. E., Stout, R. L., Morey, L. C. & McGlashan, T. H. (2004). Two-year stability and change of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Journal of Consulting and Clinical Psychology, 72, 767-775.
20. Hollander, E., Allen, A., Lopez, R. P., Bienstock, C. A., Grossman, R., Siever, L. J., Merkatz, L. & Stein, D. J. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. Journal of Clinical Psychiatry, 62, 199-203.
21. Hollander, E., Swann, A. C., Coccaro, E. F., Jiang, P. & Smith, T. B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621-624.
22. Koons, C. R., Robins, C. J., Tweed, J. L., Lynch, T. R., Gonzalez, A. M., Morse, J. Q., Bishop, G. K., Butterfield, M. I. & Bastian, L. A. (2001). Efficacy of dialectical behaviour therapy in women veterans with borderline personality disorder. Behavior Therapy, 32, 371-390.
23. Lieb, K., Zanarini, M. C., Schmahl, C. G., Linehan, M. M. & Bohus, M. (2004). Borderline personality disorder. Lancet, 364, 459-461.
24. Linehan, M. M. (1993a). Cognitive behavioral treatment of borderline personality disorder. New York: Guilford.
25. Linehan, M. M. (1993b). Skills training manual for treating borderline personality disorder. New York: Guilford.
26. Linehan, M. M., Armstrong, H. E., Suarez, A., Allmon, D. & Heard, H. L. (1991). Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry, 48, 1060-1064.
27. Linehan, M. M., Comtois, K. A., Brown, M., Reynolds, S., Welch, S., Sayrs, J. & Korslund, K. (2002, November). DBT versus nonbehavioral treatment by experts in the community: Clinical outcomes. Symposium presentation for the Association for Advancement of Behavior Therapy. University of Washington, Reno, NV.
28. Linehan, M. M., Dimeff, L. A., Reynolds, S. K., Comtois, K. A., Welch, S. S., Heagerty, P. & Kivlahan, D. R. (2002). Dialectical behaviour therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug and Alcohol Dependence, 67, 13-26.
29. Linehan, M.M., Heard, H. L. & Armstrong, H. E. (1993). Naturalistic follow-up of a behavioral treatment of chronically parasuicidal borderline patients. Archives of General Psychiatry, 50, 971-974.
30. Linehan, M. M. & Koerner, K. (1993). A behavioral theory of borderline personality disorder In J. Paris (Ed.), Borderline personality disorder (pp. 103-121). Washington, DC: American Psychiatric Press.
31. Linehan, M. M., Schmidt, H., Dimeff, L. A., Craft, J. C., Kanter, J. & Comtois, K. A. (1999). Dialectical behaviour therapy for patients with borderline personality disorder and drug-dependence. American Journal on Addiction, 8, 279-292.
32. Linehan, M. M., Turek, D. A., Heard, H. L. & Armstrong, H. E. (1994). Interpersonal outcome of cognitive behavioural treatment of chronically suicidal borderline patients. American Journal of Psychiatry, 151, 1771-1776.
33. Loranger, A. W., Sartorius, N., Andreoli, A., Berger, P., Buchheim, P., Channabasavanna, S. M., Coid, B., Dahl, A. A., Diekstra, R. F. W., Ferguson, B., Jakobsberg, L., Mombour, W., Pull, C., Ono, Y. & Regier, D. A. (1998). Deutschsprachige Fassung der International Personality Disorder Examination: IPDE. Genf: WHO.
34. Loranger, A. W. (1999). International Personality Disorder Examination (IPDE). DSM-IV and ICD-10 modules. Odesse, FL: Psychological Assessment Resources.
35. Markovitz, P. J. (1995). Pharmacotherapy of impulsivity, aggression and related disorders. In D. Stein & E. Hollander (Eds.), Impulsive aggression and disorders of impulse control (pp. 263-287). Sussex: Wiley.
36. Markovitz, P. J., Calabrese, J. R., Schulz, S.C. & Meltzer, H. Y. (1991). Fluoxetine in the treatment of borderline and schizotypal personality disorder. American Journal of Psychiatry, 148, 1064-1067.
37. Markovitz, P. J. & Wagner, S. C. (1995). Venlafaxine in the treatment of borderline personality Disorder. Psychopharmacology Bulletin, 31, 773-777.
38. Nickel, M. K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K., Krawczyk, J., Leiberich, P. K., Rother, W. K. & Loew, T. H. (2005). Treatment of aggression with topiramate in male borderline patients: A double-blind, placebo-controlled study. Biological Psychiatry, 57, 495-499.
39. Nickel, M. K., Nickel, C., Mitterlehner, F. O., Tritt, K., Lahmann, C., Leiberich, P. K., Rother, W. K. & Loew, T. H. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515-1519.
40. Norden, M. J. (1989). Fluoxetine in borderline personality disorder. Progress in Neuropsychopharmacological and Biological Psychiatry, 13, 885-893.
41. Pascual, J. C., Oller, S., Soler, J., Barrachina, J., Alvarez, E. & Pérez, V. (2004). Ziprasidone in the acute treatment of borderline personality disorder in psychiatric emergency services. Journal of Clinical Psychiatry, 65, 1281-1283.
42. Pfohl, B., Blum, N. & Zimmerman, M. (1997). Structured interview for DSM-IV personality. Washington, DC: American Psychiatric Press.
43. Philipsen, A., Feige, B., Al-Shajlawi, A., Schmahl, C., Bohus, M., Richter, H., Voderholzer, U., Lieb, K. & Riemann, D. (2005). Increased delta-power and discrepancies in objective and subjective sleep measurements in borderline personality disorder. Journal of Psychiatric Research, 39, 489-498.
44. Philipsen, A., Richter, H., Schmahl, C., Peters, J., Rüsch, N., Bohus, M. & Lieb, K. (2004). Clonidine in acute aversive inner tension and self-injurious behaviour in female patients with borderline personality disorder. Journal of Clinical Psychiatry, 65, 1414-1419.
45. Philipsen, A., Schmahl, C. & Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 1-4.
46. Pinto, O. C. & Akiskal, H. S. (1998). Lamotrigine as a promising approach to borderline personality: An open case series without concurrent DSM-IV major mood disorder. Journal of Affective Disorders, 51, 333-343.
47. Pittinger, C., Krystal, J. H. & Coric, V. (2005). Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. Journal of Clinical Psychiatry, 66, 1492-1493.
48. Rinne, T., van den Brink, W., Wouters, L. & van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054.
49. Rocca, P., Marchiaro, L., Cocuzza, E. & Bogetto, F. (2002). Treatment of borderline personality disorder with risperidone. Journal of Clinical Psychiatry, 63, 241-244.
50. Roth, A. S., Ostroff, R. B. & Hoffman, R. E. (1996). Naltrexone as a treatment for repetitive self-injurious behaviour: An open label trial. Journal of Clinical Psychiatry, 57, 233-237.
51. Salzman, C., Wolfson, A. N., Schatzberg, A., Looper, J., Henke, R., Albanese, M., Schwartz, J. & Miyawaki, E. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23-29.
52. Schmahl, C. G., Stiglmayr, C. E., Böhme, R. & Bohus, M. (1999). Behandlung von dissoziativen Symptomen bei Borderline- Persönlichkeitsstörungen mit Naltrexon. Nervenarzt, 70, 262-264.
53. Simpson, E. B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J. & Pearlstein, T. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379-385.
54. Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E. & Pérez, V. (2005). Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221-1224.
55. Soloff, P., Cornelius, J. R., George, A., Swami, N., Perel, J. M. & Ulrich, R. F. (1993). Efficacy of phenelzine and haloperidol in borderline personality disorder. Archives of General Psychiatry, 50, 377-385.
56. Soloff, P., George, A., Nathan, R. S., Schulz, P. M. & Perel, J. M. (1986a). Paradoxical effects of amitriptyline in borderline patients. American Journal of Psychiatry, 143, 1603-1605.
57. Soloff, P., George, A., Nathan, R.S., Schulz, P.M., Ulrich, R.F. & Perel, J. M. (1986b). Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol and placebo. Archives of General Psychiatry, 43, 691-697.
58. Tritt, K., Nickel, C., Lahmann, C., Leiberich, P. K., Rother, W., Loew, T. H. & Nickel, M. K. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19, 287-291.
59. Turner, R. M. (2000). Naturalistic evaluation of dialectical behaviour therapy-oriented treatment for borderline personality disorder. Cognitive and Behavioral Practice, 7, 413-419.
60. Van den Bosch, L. M. C., Verheul, R., Schippers, G. M. & van den Brink, W. (2002). Dialectical behavior therapy of borderline patients with and without substance use problems: Implementation and long-term effects. Addictive Behaviors, 27, 911-923.
61. Verheul, R., van den Bosch, L. M. C., Koeter, M. W. J., de Ridder, M. A. J., Stijnen, T. & van den Brink, W. (2003). Dialectical behavior therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. British Journal of Psychiatry, 182, 135-140.
62. Young, J. E. (1999). Cognitive therapy for personality disorders: A schema-focused approach (3rd ed.). Sarasota, FL: Professional Resource Press/Professional Resource Exchange, Inc.
63. Zanarini, M. C. (2003). Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD). A continuous measure of DSM-IV borderline psychopathology. Journal of Personality Disorders, 17, 233-242.
64. Zanarini, M. C. & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients: A double-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854.
65. Zanarini, M. C. & Frankenburg, F. R. (2003). Omega-3-fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167-169.
66. Zanarini, M. C., Frankenburg, F. R., Dubo, E. D., Sickel, A. E., Trikha, A., Levin, A. & Reynolds, V. (1998). Axis I comorbidity of borderline personality disorder. American Journal of Psychiatry, 155, 1733-1739.
67. Zanarini, M.C., Frankenburg, F.R., Hennen, J., Reich, D.B. & Silk, K. R. (2004). Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. American Journal of Psychiatry, 161, 2108-2114.
68. Zanarini, M. C., Frankenburg, F. R., Hennen, J. & Silk, K. (2003). The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. American Journal of Psychiatry, 160, 274-283.
69. Zanarini, M. C., Frankenburg, F. R. & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903-907.
70. Zanarini, M. C., Frankenburg, F. R., Sickel, A. E. & Yong, L. (1996). The diagnostic interview for DSM-IV personality disorders. Belmont, MA: McLean Hospital, Laboratory for the Study of Adult Development.
71. Zanarini, M. C., Frankenburg, F. R., Vujanovic, A. A., Hennen, J., Reich, D. B. & Silk, K. R. (2004). Axis II comorbidity of borderline personality disorder: Description of 6-year course and prediction to time-to-remission. Acta Psychiatrica Scandinavica, 110, 416-420.